Hahn Mark W's Form 4 filing
Verona Pharma plc (VRNA) · filed Dec 6, 2024
- Accession no.
- 0001104659-24-126371
- Filed
- Dec 6, 2024
- Trade date
- Dec 4-6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $4.42M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Mark WCIK 0001408502 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 4, 2024 | Ordinary Shares | SSaleDisposed | −58,184 | $5.00 | −$290,920 | 14,117,512 | Direct | |
| Dec 5, 2024 | Ordinary Shares | SSaleDisposed | −640,048 | $5.01 | −$3,206,640.48 | 13,477,464 | Direct | |
| Dec 6, 2024 | Ordinary Shares | SSaleDisposed | −183,728 | $5.01 | −$920,477.28 | 13,293,736 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.